Your First 90 Days on GLP-1: A Week-by-Week Guide

The first 90 days on GLP-1 medication represent a critical physiological and behavioral transition window. During this period, your neuro-hormonal pathways adapt, your digestive system slows down, and your relationship with food undergoes a profound shift. Understanding what lies ahead — week by week — can make the difference between a frustrating experience and a successful health transformation.

The Biological Foundation: Why the First 90 Days Matter

GLP-1 receptor agonists work through multiple mechanisms: stimulating insulin secretion, suppressing glucagon, slowing gastric emptying, and acting on the hypothalamus to reduce appetite. Because these medications work deeply on your neurological and digestive systems, your body requires a gradual introductory period — titration — to build tolerance.

Phase 1: Weeks 1-4 — Laying the Foundation

Week 1: Initiation

• First injection marks the start. Anxiety about self-administration is normal.
• Many patients notice "food noise" — intrusive food thoughts — beginning to quieten during the first week, though timing varies a great deal between individuals
• Action: Administer at consistent time, prioritize hydration (80-100 oz water daily)
• Care team: Weekly check-in to review injection technique and hydration baseline

Week 2: Identifying Satiety

• Food remains in stomach longer, fullness signals stay active for hours
• Learn your "stop signal" — the margin between satisfied and painfully full is narrow
• Focus on lean protein to protect skeletal muscle
• Skipping meals due to appetite suppression leads to muscle wasting — maintain structured eating

Week 3: Managing GI Side Effects

• Mild nausea, acid reflux, or constipation may appear
• For nausea: Avoid high-fat foods, sip ginger tea
• For reflux: Don't lie down within 3 hours of eating
• For constipation: 25-30g fiber daily, consistent water intake
• Care team NP adjusts nutrition plan based on side effect log

Week 4: First Month Assessment

• Body has adapted to initial dose
• Review energy levels, sleep quality, overall comfort
• Prepare for dose escalation

Phase 2: Weeks 5-8 — Dose Escalation

Week 5: Managing the Step-Up

• Dose increases (e.g., semaglutide 0.25mg → 0.5mg)
• May re-trigger mild side effects that had subsided
• Return to strict hydration and portion control rules
• Care team reviews logs to ensure safe escalation

Week 6: Overcoming the "Mind Plateau"

• Temporary slowdown in weight loss is normal
• Hormonal counter-regulatory mechanisms may mask fat loss
• Smart scale data shows underlying trend continues
• NP provides metabolic context to prevent frustration

Week 7-8: Behavioral Integration

• Resistance training becomes critical: 2-3 sessions/week
• Protein targets: 0.75-1.0g per pound of body weight
• Sleep optimization: 7-9 hours, consistent schedule
• Care calls shift to biweekly

Phase 3: Weeks 9-12 — Stabilization

Week 9-10: Dose Stabilization

• Reaching maintenance dose or continuing titration
• Metabolic rate optimizing with improved insulin sensitivity
• Advanced nutrition coaching: meal timing, macro cycling
• Activity tracking via smart watch reveals patterns

Week 11-12: The 90-Day Review

• Comprehensive biomarker review
• Weight trajectory analysis with care team
• Care plan adjustments for months 4-6
• Transition from induction to stabilization phase
• Contact schedule shifts from weekly to biweekly calls

The first 90 days establish the metabolic, nutritional, and behavioural foundation for everything that follows. They also cover the stretch in which side effects are most active and expectations are least calibrated. Only about 32% of patients who start a GLP-1 for obesity are still adherent at twelve months (Prime Therapeutics, 2023, Journal of Managed Care & Specialty Pharmacy). Almost every reason for stopping is something that can be handled if someone is watching: side effects during titration, a plateau nobody explained, or a question with no one to ask. That is what the structure above is for. We do not publish an adherence figure for our own patients, because we have no study that would support one.